WO2017195156A1 - Fat and medical uses thereof - Google Patents
Fat and medical uses thereof Download PDFInfo
- Publication number
- WO2017195156A1 WO2017195156A1 PCT/IB2017/052792 IB2017052792W WO2017195156A1 WO 2017195156 A1 WO2017195156 A1 WO 2017195156A1 IB 2017052792 W IB2017052792 W IB 2017052792W WO 2017195156 A1 WO2017195156 A1 WO 2017195156A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- micro
- fat
- fragmented
- fragmented fat
- disease
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/35—Fat tissue; Adipocytes; Stromal cells; Connective tissues
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
Definitions
- the present invention refers to micro-fragmented fat tissue or a composition comprising micro-fragmented fat tissue for use in the treatment of a systemic disease, preferably associated to or caused by sepsis.
- micro-fragmented fat tissue or the composition comprising micro-fragmented fat tissue is used for treating a systemic, inflammatory, immune, or chronic disease, said disease being intended as a consequence of septic disease.
- the micro-fragmented fat tissue is useful for treating both the acute (early) and late stages of sepsis.
- Sepsis or systemic inflammatory response syndrome
- Sepsis is defined as a syndrome of physiologic, pathologic, and biochemical abnormalities induced by an infection resulting in a systemic uncontrolled inflammatory response that leads to vascular leakage, tissue damage, multiorgan failure. Still currently, sepsis precipitates in 30% to 40% of cases to death since the available treatments are not very effective.
- the present invention solves the need above reported by using/administering micro-fragmented fat tissue, preferably by intraperitoneal route.
- the Applicant has surprisingly found that, for example, septic individuals treated with micro-fragmented fat tissue show a decrease of most of the detrimental effects associated to or caused by sepsis. More interestingly, the use/administration of micro-fragmented fat tissue recovered the impairments typical of both acute and late phases of sepsis. The use/administration of micro-fragmented fat tissue is particularly effective in rescuing the long-term effects associated to sepsis such as, organ dysfunctions and/or injury, muscle weakness or cognitive impairment.
- the Applicant has observed an improvement of the survival rate and a lasting decrease of septic score in mice treated with micro- fragmented fat tissue. Moreover, the treated mice showed the normalization of body temperature and biological parameters, a decrease of pro-inflammatory cytokine levels and an increase of anti-inflammatory cytokine levels. Further, treated mice also showed a decreased infiltration of immune cells in the liver and lungs. Finally, micro-fragmented fat tissue administration allows recovering of neuromyopathy and muscle weakness/wasting associated to late phase of sepsis.
- Figure 1 shows the sepsis score in CLP mice injected with Lipogems (micro-fragmented fat tissue) or saline (A-B), and the sepsis score and the survival rate in LPS-treated mice injected or not with Lipogems (micro- fragmented fat tissue) (C-D).
- Figure 2 shows the survival rate (A) and the body temperature (B) of CLP mice injected with saline or Lipogems (micro-fragmented fat tissue).
- FIG 3 shows the plasma levels (A) of alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (AP), creatine kinase (CK) and lactate dehydrogenase (LDH); the leucocyte count (B-C) in CLP ice injected with saline or Lipogems (micro-fragmented fat tissue).
- Figure 4 shows pro-inflammatory cytokine levels In CLP mice injected or not with Lipogems (micro-fragmented fat tissue).
- Figure 5 shows the number of F4/80+, B220+ and CD3+ cells in the liver and kidney of CLP mice injected or not with Lipogems (micro-fragmented fat tissue).
- a first aspect of the present invention refers to micro-fragmented fat tissue or a composition comprising micro-fragmented fat tissue for use in the treatment of a systemic disease or a systemic condition, preferably a systemic disease or a systemic condition associated with or caused by sepsis.
- the micro-fragmented fat tissue is useful to improve (to recover and/or to rescue) the detrimental health effects associated with a systemic disease or systemic condition, preferably associated with or caused by sepsis, preferably the long term effects associated to or caused by sepsis.
- a first aspect of the present invention refers to a method for treating a systemic condition or a systemic disease, preferably a disease/condition associated with or caused by sepsis, said method comprising at least one step of administering to an individual in need thereof an effective amount of micro-fragmented fat tissue or a composition comprising micro-fragmented fat tissue.
- the disease or condition is preferably a systemic, inflammatory, immune, or chronic disease/condition, said disease/condition being intended caused by a septic disease/condition.
- the disease or the condition is related to prostaglandin synthesis and/or non-COX targets. Therefore, the condition or disease is non-COX targets mediated.
- systemic condition or systemic disease is defined as a condition or a disease affecting a number of organs and tissues, or even the body as a whole.
- sepsis means also a systemic inflammatory response syndrome.
- sepsis or systemic inflammatory response syndrome means an infection resulting in systemic uncontrolled inflammatory response leading to vascular leakage, tissue damage and/or multiorgan failure.
- these effects can cause neuromyopathy, muscle weakness, energetic dysfunction, proteolysis, muscle wasting and, in the end, even the death of septic individual.
- the detrimental health effects related to sepsis are preferably selected from: neuromyopathy, energetic dysfunction, proteolysis, muscle wasting, acute kidney and liver injury, multiple organ dysfunction, and possibly death.
- the acute phase damaging effects are selected from: change in body temperature, cytokine storm (huge and rapid increase) and PCT (Pro-calcitonin) increase.
- the late phase detrimental effects are preferably selected from: organ dysfunctions and/or injury, acute lung injury, shock, renal failure, muscle loss and/or weakness, cognitive impairment (insomnia, nightmares, vivid hallucinations and panic attacks, extreme fatigue, poor concentration, decreased mental functioning, loss of self-esteem and self-belief), and multiple organ dysfunction syndrome (MODS).
- organ dysfunctions and/or injury acute lung injury, shock, renal failure, muscle loss and/or weakness
- cognitive impairment insomnia, nightmares, vivid hallucinations and panic attacks, extreme fatigue, poor concentration, decreased mental functioning, loss of self-esteem and self-belief
- MODS multiple organ dysfunction syndrome
- the micro-fragmented fat tissue is non-enzymatic micro- fragmented fat tissue.
- the fat used/administered in the present invention has been micro-fragmented without any enzymatic treatment.
- the micro-fragmented fat tissue preferably lipoaspirate
- the micro-fragmented fat tissue is obtained by using the Lipogems ® device, more preferably according to the process as fully disclosed in the patent application WO201 1 /145075.
- the isolated fat is introduced in the Lipogems ® device and it is progressively reduced (fragmented) in small clusters of tissue by means of mild mechanical forces and in presence of a solution, preferably a saline solution.
- a solution preferably a saline solution.
- the micro-fragmented fat contains clusters of fat having size ranging from 50 to 5000 ⁇ , preferably from 100 to 3000 ⁇ , more preferably from 200 to 2500 ⁇ , more preferably from 300 to 1500 ⁇ , more preferably from 400 to 900 ⁇ .
- these clusters of fat comprise Mesenchymal Stem Cells (MSCs) and/or pericytes, preferably pericytes-associated MSCs and/or Adipose Stem Cells and/or endothelial cells and/or fibroblasts and/or adipocytes.
- MSCs Mesenchymal Stem Cells
- pericytes-associated MSCs preferably pericytes-associated MSCs and/or Adipose Stem Cells and/or endothelial cells and/or fibroblasts and/or adipocytes.
- the micro- fragmented fat tissue preferably the microfragmented lipoaspirate has higher content of microvessels, preferably higher content of CD31 + cells, more preferably at 5-10 times higher content of CD31 + cells, compared to the non micro-fragmented tissue, that is the fat tissue, preferably lipoaspirate that did not undergo to the microfragmentation process disclosed in the present application and in the patent application WO201 1 /145075.
- the micro- fragmented fat tissue preferably the microfragmented lipoaspirate has higher content of larger vessels and/or number of pericytes, thai is NG2 positive cells, compared to the non micro-fragmented tissue, that is the fat tissue, preferably lipoaspirate that did not undergo to the microfragmentation process disclosed in the present application and in the patent application WO201 1 /145075.
- the micro-fragmented fat tissue preferably the microfragmented lipoaspirate of the present invention preferably comprises:
- Clusters of tissue having size ranging from 50 to 5000 ⁇ ;
- MSCs Mesenchymal Stem Cells
- pericytes preferably pericytes- associated MSCs and/or Adipose Stem Cells and/or endothelial cells and/or fibroblasts and/or adipocytes; and/or
- It is preferably free from blood residues and pro-inflammatory oily substances.
- These cells express at least one, preferably all, marker selected from: CD44, CD73, CD90, CD105, CD146 and CD166 and preferably also at least one marker, more preferably all, selected from OCT4, SOX2, NANOG, b-tubulin III NESTIN, NEUROD1 , MUSASHI1 , PAX6, and SOX3. More preferably, these cells co-express nestin, b-tubulin III, GFAP, and 04.
- Controlled fat fragmentation is allowed by using one or more fragmentation/disaggregation means contained into the device.
- the means are metallic means, more preferably metallic beads, wherein said beads have preferably size ranging from 0,1 -30 millimeters, preferably 1 -20 mm, more preferably 5-10 mm, more preferably 7,5-8,5 mm.
- the controlled shaking of the device allows mild movements of the fragmentation/disgregation means throughout the fat tissue and therefore a gentle fat fragmentation/disgregation.
- the fragmentation/disgregation is performed in flowing saline buffer, more preferably continuous flow of saline buffer allowing oil and blood residues removal.
- the fat fragmentation/disgregation step takes preferably 15-20 minutes. Therefore, the micro-fragmented fat tissue of the present invention is obtained by using a gentle, enzyme-free, sterile, intra-operative and rapid manipulation.
- the fat tissue of the present invention is preferably of human origin.
- the fat tissue is human adipose tissue, more preferably human adipose tissue, more preferably isolated/lipoaspirate from the lower and/or the lateral abdomen area of an individual.
- said fat tissue can be isolated from any useful body area.
- the fat tissue preferably the micro-fragmented fat tissue is autologous or heterologous.
- the individual affected by sepsis is a human being.
- the sepsis is hospital acquired or it is associated with a bacterial, fungal or vital infection.
- the sepsis condition/disease according to the present invention involves the mis-regulation of pro-inflammatory molecules said molecules being preferably selected from but not limited to: IL-1 a, IL-1 b, IL-2, IL-5, IL-6, IL-12, IL-17, GM-CSF, IFN-g, MIP-1 a, MIP-1 b, RANTES,
- PCT procalcitonin
- CK creatine kinase
- the sepsis condition/disease according to the present invention involves the mis-regulation of anti-inflammatory molecules said molecules being preferably selected from but not limited to: IL-4, IL-10, IL-13 and G- CSF.
- the anti-inflammatory molecules are up-regulated, while the pro-inflammatory molecules are down-regulated.
- the micro-fragmented fat can be used/administered for decreasing pro-inflammatory molecules, preferably selected from but not limited to: IL-1 a, IL-1 b, IL-2, IL-5, IL-6, IL-12, IL-17, GM-CSF, IFN-g, MIP- 1 a, MIP-1 b, RANTES and/or for increasing anti-inflammatory molecules, preferably selected from: IL-4, IL-10, IL-13 and G-CSF.
- pro-inflammatory molecules preferably selected from but not limited to: IL-1 a, IL-1 b, IL-2, IL-5, IL-6, IL-12, IL-17, GM-CSF, IFN-g, MIP- 1 a, MIP-1 b, RANTES and/or for increasing anti-inflammatory molecules, preferably selected from: IL-4, IL-10, IL-13 and G-CSF.
- the micro- fragmented fat for use in the treatment of a systemic disease or condition preferably sepsis or a condition associated with (caused by) sepsis is for intraperitoneal, intramuscular, alveolar, nasal, pulmonary, intrathecal, via cribriform plate (lamina cribra), preferably using nasal route, or lymphatic administration.
- the most preferred administration route is intraperitoneal route.
- the micro-fragmented fat tissue or the composition comprising the micro-fragmented fat tissue is administered as such or in combination with further molecules, preferably anti-inflammatory and/or antibiotic agents.
- the administration is associated with or it follows further treatments:
- vasoactives such as catecholamines
- Corticotherapy preferably at low dose
- the use/administration takes place within the first 6 hours (called the golden hours in the medical community) from when sepsis symptoms appear according to the current clinical practice dosage.
- the use/administration takes place few days and/or weeks after sepsis symptoms have appeared.
- CLP Caecal Ligation and Puncture
- LPS lipopolysaccharide
- the Caecal Ligation and Puncture 20 (CLP) model was composed of a peritonitis induced by CLP as a model of inflammation in males, 6 to 10 weeks old C57BI/6RJRJ.
- the CLP model consists of the perforation of the caecum allowing the release of faecal material into the peritoneal cavity to generate an exacerbated immune response induced by polymicrobial infection. Mice that undergo CLP with fluid resuscitation show the first (early) hyperdynamic phase that in time progresses to the second (late) hypodynamic phase.
- mice were anesthetized with ketamine (Imalgenel OOO 100mg/Kg Merial) and Xylazine (Rompun 2% 20mg/Kg Bayer) ip prior to surgery. After laparotomy, caecum was ligatured at the distal third with a 4.0 suture and the distal part was perforated twice with a 21 Gauge needle. All groups of mice were hydrated and treated with analgesic (Buprenorphin Axience 0.3mg/kg) twice a day for 4d following surgery.
- analgesic Borenorphin Axience 0.3mg/kg
- LPS was administered intraperitoneal ⁇ to reach 10mg/Kg, from a 10mg/ml stock solution stored in 0.9%NaCI corrected according to the mice weight. This group was performed to confirm the effect of Lipogems ® on the primary objectives (inflammatory score and survival rate) only.
- control animals were only anesthetized with ketamine (Imalgenel OOO 100mg/Kg Merial) and Xylazine (Rompun2% 20mg/Kg Bayer) ip at the same doses. All surgical procedures were carried out during the morning under a sterile hood.
- the harvested adipose tissue was immediately processed in the Lipogems ® closed system.
- the mechanical processes of micro- fragmentation, wash, and filtration take place in a system completely immersed in physiological solution avoiding the presence of air, in order to make possible the reduction in volume and minimize any traumatic action on cellular products.
- the resulting product contains pericytes/MSCs retained within an intact stromal vascular niche, being ready to interact with the recipient tissue after transplantation.
- the purified Lipogems ® adipose tissue was collected in a 60 cc syringe and positioned to gently decant by gravity in order to remove excessive saline solution. Then the Lipogems ® product was transferred in several 1 cc syringes to be reinjected intraperitoneal ⁇ in the recipient mouse.
- mice subjected to injections of cyclooxygenase inhibitors where injected intraperitoneal ⁇ at the time of Lipogems ® delivery. Injections were performed either with Indomethacin (a nonselective inhibitor of COX enzymes used at 10mg/kg; Sigma-Aldrich, I7378, USA), or SC-560 (a selective inhibitor of the COX1 , used at 6mg/kg; Sigma-Aldrich, S2064, USA) or with NS-398 (a selective inhibitor of the COX2 used at 6mg/Kg; Sigma-Aldrich, N194, USA). Injections were performed every 8 hours for 24 hours. All injections were body weight corrected, starting from a
- H&E Hematoxylin and Eosin Staining and Immunohistochemistrv
- organs were fixed in 4% formaldehyde for 2 days, and embedded in paraffin at 60°C. Tissues were then sectioned at 50 ⁇ and left overnight dry. Sections were dipped in hematoxylin for 30 seconds. After being washed with alcohol acid and ammonia water, they were immersed in eosin for 15 seconds. After each step, sections were rinsed with distilled water. The sections then were dehydrated by treatment with alcohols of increasing concentrations (70%, 80%, 95%, and 100%). Finally, the sections were treated with xylene and covered with glass slips.
- the list of antibodies used was the following: anti-CD3, Dako#A0452; anti-CD4 Pharmigen#550280; anti-F4/80 lnvitrogen#RM2600; anti-CD45R (B220) Invitrogen #A14748; anti- biotinylated Jackson # 712065150.
- the primary endpoint was the evaluation of the inflammatory score 24 hours after CLP (table 1 ). For comparative and confirmation purpose, this score was also calculated at 24 hours in mice injected with 10 mg/kg ip LPS.
- the measured secondary endpoints included survival and body temperature until day 21 post-inflammation, plasma levels of aspartate aminotransferase (ASAT), alanine aminotransferase (ALAT), alkaline phosphatase (AP), lactate deshydrogenase (LDH) and creatine kinase (CK) leucocyte count, and plasma levels of pro- and anti-inflammatory cytokines at 24 hours and until the 21 st day post CLP, the number of F4/80+, B220+ and CD3+ cells in the liver and kidney 6 hours post CLP.
- ASAT aspartate aminotransferase
- ALAT alanine aminotransferase
- AP alkaline phosphatase
- LDH lactate deshydrogenase
- CK creatine kinase
- data are represented as median[IQR], except for body temperature, quantity of cytokines and leucocyte count that are displayed with mean ⁇ SD. *P ⁇ 0.05; **P ⁇ 0.01 ; ***P ⁇ 0.001 ; ns, statistically non-significant, compared to the respective control.
- Plasma levels of aspartate aminotransferase (ASAT), alanine aminotransferase (ALAT), alkaline phosphatase (AP), lactate deshydrogenase (LDH) and creatine kinase (CK) were statistically higher 24 hours post inflammation in CLP mice compared to the control noninflammatory groups ( Figure 3A).
- ASAT aspartate aminotransferase
- ALAT alanine aminotransferase
- AP alkaline phosphatase
- LDH lactate deshydrogenase
- CK creatine kinase
- Plasma levels of the pro-inflammatory cytokines IL-1 , IL-2, IL-5, IL-6, IL-17, IFN-g, MIP-1 , TNF-a were augmented when septic (CLP) mice were injected with Lipogems ® plus indomethacin (Figure 6D, Table II) compared to
- SC-560 When using the specific cyclooxygenase-1 inhibitor SC-560, only IL-17 plasma level was increased, whilst all the other pro-inflammatory cytokines were not changed compared to CLP mice injected with Lipogems alone (Table II).
- mice body temperature is close to 37°C
- the levels of pro-inflammatory cytokines decrease while the levels of antiinflammatory cytokines increase.
- Further treatment of septic mice, such as Lipoaspirate intraperitoneally administration did not show the same results.
- the data reported above demonstrate that Lipogems® micro- fragmented fat acts via prostaglandin pathway.
- the enzymatic activity of COX-2 is critical for its anti-inflammatory effect.
- indomethacin a potent prostaglandin synthesis suppressor
- administration blocks the effects of Lipogems® micro-fragmented fat administration in septic mice. Therefore, Lipogems® micro-fragmented fat affects prostaglandin synthesis and non-COX targets.
- Micro-fragmented fat with Lipogems extraction was shown to diminish the inflammation during acute phase of sepsis.
- One of the long-term effect of sepsis can be 1 ) muscle weakness that can last for 5 years and 2) cognitive impairment.
- Lipogems micro-fragmented fat tissue
- the microglial cells - the immune cells of the brain - are less impaired.
- Lipogems injection reduces the microglial cells deramification in the frontal cortex and hippocampus of septic mice and therefore Lipogems injection at the chronic phase of sepsis improves microglial cells behavior.
- micro-fragmented fat injection prevents or ameliorates/reduces the cognitive impairment associated to/caused by sepsis.
Abstract
Description
Claims
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16/301,374 US20200316133A1 (en) | 2016-05-13 | 2017-05-12 | Fat and medical uses thereof |
CN201780029334.3A CN109414456A (en) | 2016-05-13 | 2017-05-12 | Fat and its medical application |
BR112018073355-5A BR112018073355A2 (en) | 2016-05-13 | 2017-05-12 | fat and its medical uses |
JP2018559219A JP2019514997A (en) | 2016-05-13 | 2017-05-12 | Fat and its medical use |
EP17727711.8A EP3454872A1 (en) | 2016-05-13 | 2017-05-12 | Fat and medical uses thereof |
AU2017261919A AU2017261919B2 (en) | 2016-05-13 | 2017-05-12 | Fat and medical uses thereof |
CA3023814A CA3023814A1 (en) | 2016-05-13 | 2017-05-12 | Fat and medical uses thereof |
JP2022110421A JP2022133458A (en) | 2016-05-13 | 2022-07-08 | Fat and medical uses thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT102016000049360 | 2016-05-13 | ||
ITUA2016A003417A ITUA20163417A1 (en) | 2016-05-13 | 2016-05-13 | Fat and medical uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2017195156A1 true WO2017195156A1 (en) | 2017-11-16 |
Family
ID=56894170
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2017/052792 WO2017195156A1 (en) | 2016-05-13 | 2017-05-12 | Fat and medical uses thereof |
Country Status (9)
Country | Link |
---|---|
US (1) | US20200316133A1 (en) |
EP (1) | EP3454872A1 (en) |
JP (2) | JP2019514997A (en) |
CN (1) | CN109414456A (en) |
AU (1) | AU2017261919B2 (en) |
BR (1) | BR112018073355A2 (en) |
CA (1) | CA3023814A1 (en) |
IT (1) | ITUA20163417A1 (en) |
WO (1) | WO2017195156A1 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10589268B2 (en) | 2016-06-08 | 2020-03-17 | The Regents Of The University Of California | Method and device for processing tissues and cells |
US10683480B2 (en) | 2013-06-21 | 2020-06-16 | The Regents Of The University Of California | Microfluidic tumor tissue dissociation device and method |
US10722540B1 (en) | 2016-02-01 | 2020-07-28 | The Regents Of The University Of California | Microfluidic device and method for shear stress-induced transformation of cells |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ITUA20163417A1 (en) * | 2016-05-13 | 2017-11-13 | Lipogems Int Spa | Fat and medical uses thereof |
CN114886922A (en) * | 2022-05-25 | 2022-08-12 | 温州医科大学附属第一医院 | Medicine containing fat micro-segment and application thereof in treatment of chronic wound surface difficult to heal |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011145075A2 (en) | 2010-05-20 | 2011-11-24 | Carlo Tremolada | Device and method for preparing tissue, particularly adipose tissue, for transplantation from lobular fat extracted by liposuction |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ITUA20163417A1 (en) * | 2016-05-13 | 2017-11-13 | Lipogems Int Spa | Fat and medical uses thereof |
-
2016
- 2016-05-13 IT ITUA2016A003417A patent/ITUA20163417A1/en unknown
-
2017
- 2017-05-12 CN CN201780029334.3A patent/CN109414456A/en active Pending
- 2017-05-12 CA CA3023814A patent/CA3023814A1/en active Pending
- 2017-05-12 JP JP2018559219A patent/JP2019514997A/en active Pending
- 2017-05-12 WO PCT/IB2017/052792 patent/WO2017195156A1/en unknown
- 2017-05-12 US US16/301,374 patent/US20200316133A1/en active Pending
- 2017-05-12 BR BR112018073355-5A patent/BR112018073355A2/en unknown
- 2017-05-12 EP EP17727711.8A patent/EP3454872A1/en active Pending
- 2017-05-12 AU AU2017261919A patent/AU2017261919B2/en active Active
-
2022
- 2022-07-08 JP JP2022110421A patent/JP2022133458A/en active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011145075A2 (en) | 2010-05-20 | 2011-11-24 | Carlo Tremolada | Device and method for preparing tissue, particularly adipose tissue, for transplantation from lobular fat extracted by liposuction |
Non-Patent Citations (4)
Title |
---|
BETTINA LINDROOS ET AL: "The Potential of Adipose Stem Cells in Regenerative Medicine", STEM CELL REVIEWS AND REPORTS, HUMANA PRESS INC, NEW YORK, vol. 7, no. 2, 18 September 2010 (2010-09-18), pages 269 - 291, XP019895296, ISSN: 1558-6804, DOI: 10.1007/S12015-010-9193-7 * |
FANUEL MESSAGGIO: "Mesenchymal Stem Cells from human adipose tissue", DOTTORATO IN SCIENZE BIOCHIMICHE, NUTRIZIONALI E METABOLICHE, 1 January 2013 (2013-01-01), XP055333762, Retrieved from the Internet <URL:http://lipogems.eu/docs/pubblicazioni/Messaggio-2013.pdf> [retrieved on 20170110] * |
GONZALEZ-REY E ET AL: "Human adult stem cells derived from adipose tissue protect against experimental colitis and sepsis", GUT, BRITISH MEDICAL ASSOCIATION, LONDON, UK, vol. 58, no. 7, 1 July 2009 (2009-07-01), pages 929 - 939, XP009186144, ISSN: 0017-5749, DOI: 10.1136/GUT.2008.168534 * |
WILLIAM P CAWTHORN ET AL: "Adipose tissue stem cells: the great WAT hope", TRENDS IN ENDOCRINOLOGY AND METABOLISM, vol. 23, no. 6, 30 June 2012 (2012-06-30), pages 270 - 277, XP028513009, ISSN: 1043-2760, [retrieved on 20120130], DOI: 10.1016/J.TEM.2012.01.003 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10683480B2 (en) | 2013-06-21 | 2020-06-16 | The Regents Of The University Of California | Microfluidic tumor tissue dissociation device and method |
US11427798B2 (en) | 2013-06-21 | 2022-08-30 | The Regents Of The University Of California | Microfluidic tissue dissociation device and method |
US10722540B1 (en) | 2016-02-01 | 2020-07-28 | The Regents Of The University Of California | Microfluidic device and method for shear stress-induced transformation of cells |
US10589268B2 (en) | 2016-06-08 | 2020-03-17 | The Regents Of The University Of California | Method and device for processing tissues and cells |
US11130127B2 (en) | 2016-06-08 | 2021-09-28 | The Regents Of The University Of California | Method and device for processing tissues and cells |
Also Published As
Publication number | Publication date |
---|---|
CA3023814A1 (en) | 2017-11-16 |
JP2022133458A (en) | 2022-09-13 |
JP2019514997A (en) | 2019-06-06 |
ITUA20163417A1 (en) | 2017-11-13 |
BR112018073355A2 (en) | 2019-03-06 |
CN109414456A (en) | 2019-03-01 |
AU2017261919A1 (en) | 2018-11-22 |
US20200316133A1 (en) | 2020-10-08 |
AU2017261919B2 (en) | 2023-02-23 |
EP3454872A1 (en) | 2019-03-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2017261919B2 (en) | Fat and medical uses thereof | |
Zhang et al. | Curcumin regulated shift from Th1 to Th2 in trinitrobenzene sulphonic acid-induced chronic colitis | |
Kim et al. | Antioxidant and anti-inflammatory effects of intravenously injected adipose derived mesenchymal stem cells in dogs with acute spinal cord injury | |
Lee et al. | Allo-transplantation of mesenchymal stem cells attenuates hepatic injury through IL1Ra dependent macrophage switch in a mouse model of liver disease | |
Wang et al. | Ozone protects the rat lung from ischemia-reperfusion injury by attenuating NLRP3-mediated inflammation, enhancing Nrf2 antioxidant activity and inhibiting apoptosis | |
Promoda Perera et al. | NLRP3 inhibitors as potential therapeutic agents for treatment of inflammatory bowel disease | |
van der Helm et al. | Local but not systemic administration of mesenchymal stromal cells ameliorates fibrogenesis in regenerating livers | |
WO2022242189A1 (en) | Application of exosomes derived from stem cells in preparing medicine for treating chronic obstructive pulmonary diseases | |
EP3500308A1 (en) | Inhibition of sphingosine 1-phosphate receptor for treatment and prevention of lymphedema | |
US20220387561A1 (en) | Treatment of severe acute respiratory syndrome-related coronavirus infection with klotho | |
Xie et al. | Val‐Val‐Tyr‐Pro protects against non‐alcoholic steatohepatitis in mice by modulating the gut microbiota and gut‐liver axis activation | |
Weichmann et al. | Projected supportive effects of PycnogenolⓇ in patients suffering from multi-dimensional health impairments after a SARS-CoV2 infection | |
JP2016069495A (en) | Indoxyl sulfate production inhibitor | |
Razi et al. | Mesenchymal stem cells in the treatment of new coronavirus pandemic: a novel promising therapeutic approach | |
Gharazi et al. | Protective effect of a formulation containing Pistacia atlantica oleo-gum-resin and honey on experimental model of acetic acid-induced colitis in rats | |
WO2021210026A1 (en) | A cell-free growth factor concentrate, method of preparing the same and a kit thereof | |
US20180117067A1 (en) | Methods and compositions for treating pancreatitis | |
Wei et al. | Human umbilical cord-derived mesenchymal stem cells ameliorate perioperative neurocognitive disorder by inhibiting inflammatory responses and activating BDNF/TrkB/CREB signaling pathway in aged mice | |
JP2016074692A (en) | Agent for complete remission of pollinosis provided by making symptoms of pollinosis fulminant | |
Aufderheide et al. | The resuscitation outcomes consortium (ROC) primed impedance threshold device (ITD) cardiac arrest trial: A prospective, randomised, double-blind, controlled clinical trial | |
Attia et al. | Alleviation of pulmonary fibrosis by the dual PPAR agonist saroglitazar and breast milk mesenchymal stem cells via modulating TGFß/SMAD pathway | |
RU2815888C1 (en) | Method for simulating isoproterenol-induced chronic heart failure in rats aged 24 months | |
JP6373963B2 (en) | Factor H for transplantation | |
US20220096542A1 (en) | Augmentation of natural killer cell activity and induction of cytotoxic immunity using leukocyte lysate activated allogeneic dendritic cells: stemvacs | |
WO2007011960A3 (en) | Methods and agents to treat autoimmune diseases |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
ENP | Entry into the national phase |
Ref document number: 3023814 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2018559219 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112018073355 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 2017261919 Country of ref document: AU Date of ref document: 20170512 Kind code of ref document: A |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 17727711 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2017727711 Country of ref document: EP Effective date: 20181213 |
|
ENP | Entry into the national phase |
Ref document number: 112018073355 Country of ref document: BR Kind code of ref document: A2 Effective date: 20181113 |